[{"id":"ea15e0f9-b7e9-49da-a30e-c1ac7ec36681","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272413","created_at":"2021-01-18T10:41:14.867Z","updated_at":"2024-07-02T16:36:51.449Z","phase":"Phase 3","brief_title":"Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer","source_id_and_acronym":"NCT02272413","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 695502 (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 671","initiation":"Initiation: 07/08/2015","start_date":" 07/08/2015","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 11/16/2018","study_completion_date":" 11/16/2018","last_update_posted":"2020-01-13"}]